ReviewNPJ breast cancer2023

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer.

Mark Pegram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.